BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex

  • Park, Byoung Kwon (Center for Medical Science Research, College of Medicine, Hallym University) ;
  • Maharjan, Sony (Center for Medical Science Research, College of Medicine, Hallym University) ;
  • Lee, Su In (Center for Medical Science Research, College of Medicine, Hallym University) ;
  • Kim, Jinsoo (Department of Microbiology, College of Medicine, Hallym University) ;
  • Bae, Joon-Yong (Department of Microbiology, College of Medicine, and the Institute for Viral Diseases, Korea University) ;
  • Park, Man-Seong (Department of Microbiology, College of Medicine, and the Institute for Viral Diseases, Korea University) ;
  • Kwon, Hyung-Joo (Center for Medical Science Research, College of Medicine, Hallym University)
  • Received : 2018.08.08
  • Accepted : 2018.10.11
  • Published : 2019.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) uses the spike (S) glycoprotein to recognize and enter target cells. In this study, we selected two epitope peptide sequences within the receptor binding domain (RBD) of the MERS-CoV S protein. We used a complex consisting of the epitope peptide of the MERS-CoV S protein and CpG-DNA encapsulated in liposome complex to immunize mice, and produced the monoclonal antibodies 506-2G10G5 and 492-1G10E4E2. The western blotting data showed that both monoclonal antibodies detected the S protein and immunoprecipitated the native form of the S protein. Indirect immunofluorescence and confocal analysis suggested strong reactivity of the antibodies towards the S protein of MERS-CoV virus infected Vero cells. Furthermore, the 506-2G10G5 monoclonal antibody significantly reduced plaque formation in MERS-CoV infected Vero cells compared to normal mouse IgG and 492-1G10E4E2. Thus, we successfully produced a monoclonal antibody directed against the RBD domain of the S protein which could be used in the development of diagnostics and therapeutic applications in the future.

Keywords

References

  1. Zumla A, Chan JF, Azhar EI et al (2016) Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 15, 327-347 https://doi.org/10.1038/nrd.2015.37
  2. Du L, Yang Y, Zhou Y et al (2017) MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets 21, 131-143 https://doi.org/10.1080/14728222.2017.1271415
  3. Mackay IM and Arden KE (2015) MERS coronavirus: diagnostics, epidemiology and transmission. Virol J 12, 222 https://doi.org/10.1186/s12985-015-0439-5
  4. Zaki AM, van Boheemen S, Bestebroer TM et al (2012) Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367, 1814-1820 https://doi.org/10.1056/NEJMoa1211721
  5. Omrani AS, Al-Tawfiq JA and Memish ZA (2015) Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction. Pathog Glob Health 109, 354-362 https://doi.org/10.1080/20477724.2015.1122852
  6. World Health Organization, Middle East respiratory syndrome coronavirus (MERS-CoV), 2018. (http://www.who.int/emergencies/mers-cov/en/)
  7. Ki M (2015) 2015 MERS outbreak in Korea: hospital-tohospital transmission. Epidemiol Health 37, e2015033 https://doi.org/10.4178/epih/e2015033
  8. Durai P, Batool M, Shah M and Choi S (2015) Middle East respiratory syndrome coronavirus: transmission, virology and therapeutic targeting to aid in outbreak control. Exp Mol Med 47, e181 https://doi.org/10.1038/emm.2015.76
  9. Lambour J, Naranjo-Gomez M, Piechaczyk M and Pelegrin M (2016) Converting monoclonal antibody-based immunotherapies from passive to active: bringing immune complexes into play. Emerg Microbes Infect 5, e92 https://doi.org/10.1038/emi.2016.97
  10. Scott AM, Allison JP and Wolchok JD (2012) Monoclonal antibodies in cancer therapy. Cancer Immun 12, 14
  11. Wang Q, Wong G, Lu G et al (2016) MERS-CoV spike protein: Targets for vaccines and therapeutics. Antiviral Res 133, 165-177 https://doi.org/10.1016/j.antiviral.2016.07.015
  12. Gao J, Lu G, Qi J et al (2013) Structure of the fusion core and inhibition of fusion by a heptad repeat peptide derived from the S protein of Middle East respiratory syndrome coronavirus. J Virol 87, 13134-13140 https://doi.org/10.1128/JVI.02433-13
  13. Wang N, Shi X, Jiang L et al (2013) Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res 23, 986-993 https://doi.org/10.1038/cr.2013.92
  14. Raj VS, Mou H, Smits SL et al (2013) Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251-254 https://doi.org/10.1038/nature12005
  15. Kim D, Kwon HJ and Lee Y (2011) Activation of Toll-like receptor 9 and production of epitope specific antibody by liposome-encapsulated CpG-DNA. BMB Rep 44, 607-612 https://doi.org/10.5483/BMBRep.2011.44.9.607
  16. Rhee JW, Kim D, Park et al (2012) Immunization with a hemagglutinin-derived synthetic peptide formulated with a CpG-DNA-liposome complex induced protection against lethal influenza virus infection in mice. PLoS One 7, e48750 https://doi.org/10.1371/journal.pone.0048750
  17. Park BK, Choi SH, Kim YE et al (2015) Monoclonal antibodies against the human respiratory syncytial virus obtained by immunization with epitope peptides and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother 34, 101-109 https://doi.org/10.1089/mab.2014.0089
  18. Park BK, Lee SI, Bae JY et al (2018) Production of a Monoclonal Antibody targeting the M protein of MERSCoV for detection of MERS-CoV using a synthetic peptide epitope formulated with a CpG-DNA-liposome complex. Int J Pept Res Ther https://doi.org/10.1007/s10989-018-9731-8
  19. Salazar G, Zhang N, Fu TM and An Z (2017) Antibody therapies for the prevention and treatment of viral infections. NPJ Vaccines 2, 19 https://doi.org/10.1038/s41541-017-0019-3
  20. Park BK, Park JY, Kim TH et al (2018) Production of an anti-TM4SF5 monoclonal antibody and its application in the detection of TM4SF5 as a possible marker of a poor prognosis in colorectal cancer. Int J Oncol 53, 275-285
  21. Wu G, Maharjan S, Kim D et al (2018) A Novel monoclonal antibody targets mucin1 and attenuates growth in pancreatic cancer model. Int J Mol Sci 19, 2004 https://doi.org/10.3390/ijms19072004
  22. Park BK, Gautam A, Maharjan S et al (2017) Production of anti-c-Myc monoclonal antibody inhibiting DNA binding of c-Myc and max dimer by epitope peptide-CpGDNA-liposome complex without carriers. Int J Pept Res Ther https://doi.org/10.1007/s10989-017-9649-6
  23. Wu G, Kim D, Kim JN et al (2018) A Mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed Mucin1 in breast cancer. Theranostics 8, 78-91 https://doi.org/10.7150/thno.21278
  24. Kim D, Kwon S, Rhee JW et al (2011) Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 12, 29 https://doi.org/10.1186/1471-2172-12-29
  25. Yokoyama WM, Christensen M, Santos GD and Miller D (2006) Production of monoclonal antibodies. Curr Protoc Immunol 102, Unit 2.5
  26. Maharjan S, Park BK, Lee SI et al (2018) Gomisin G inhibits the growth of triple-negative breast cancer cells by suppressing AKT phosphorylation and decreasing cyclin D1. Biomol Ther (Seoul) 26, 322-327 https://doi.org/10.4062/biomolther.2017.235
  27. Maharjan S, Park BK, Lee SI et al (2018) Gomisin G suppresses the growth of colon cancer cells by attenuation of AKT phosphorylation and arrest of cell cycle progression. Biomol Ther (Seoul) https://doi.org/10.4062/biomolther.2018.054
  28. Jo HS, Eum WS, Park EY et al (2017) Effects of PEP-1-FK506BP on cyst formation in polycystic kidney disease. BMB Rep 50, 460-465 https://doi.org/10.5483/BMBRep.2017.50.9.090
  29. Lee EW, Oh W, Song HP and Kim WK (2017) Phosphorylation of p53 at threonine 155 is required for Jab1-mediated nuclear export of p53. BMB Rep 50, 373-378 https://doi.org/10.5483/BMBRep.2017.50.7.077